Navigation Links
Biopure Announces 2008 First Quarter Financial Results
Date:2/21/2008

ket the product.

Statements in this release that are not strictly historical are forward- looking statements, including those statements implying that any clinical trial will be initiated and/or carried out to completion or that study results will be as desired, statements regarding future scientific publications and presentations on behalf of the Company and any statements that might imply that Hemopure may receive marketing approval in the United Kingdom or any other jurisdictions or for additional indications. Actual results and their timing may differ materially from those projected in these forward- looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the Company's financial position, including its limited cash resources and need to raise additional capital to pursue its business, unexpected costs and expenses, delays and adverse determinations by regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, and with product distributors, sales agents or other third parties, delays in clinical trials, and the other factors identified under the heading "Risk Factors" in the Company's annual report on Form 10-K filed on January 29, 2008, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward- looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the Company's operations and financial condition can be found in the company's filings with the SEC.

The content of this press release does not necessarily reflect the position or the policy of the U.S. Government or the Department of Defense, and no official endorsement should be inferred.


'/>"/>

SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Biopure Launches Updated Website
2. Biopure Announces Pricing of Equity Offering
3. Biopure Gives Update on Malaysia Joint Venture Discussions
4. PPD Announces Plan to Repurchase Shares of its Common Stock
5. 3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results
6. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
7. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
8. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
9. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
10. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
11. 3SBio Inc. Announces Change to the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... VANCOUVER , Aug. 26, 2015 /PRNewswire/ - iCo ... ICOTF), today reported financial results for the quarter ... are expressed in Canadian dollars and presented under ... continue pre-clinical activities with respect to our Oral ... of a contract manufacturer," said Andrew Rae ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes ... the University of Miami Miller School of Medicine, ... clinical trial to test for the first time ... successfully completed.  This FDA approved Phase I/II study ... transplantation and is an important first step toward ...
(Date:8/26/2015)... BEIJING , August 26, 2015 ... DiaCardio wins 1 st place  Wayerz ... led in Israel by venture capital fund ... countries including the US, China , ... Latin America .  Impressive achievement for the Israeli ...
(Date:8/26/2015)... 26, 2015 Despite recent ... the optimism in biotech,s forecast is the recent ... sciences advancements.  Active biotechnology & healthcare companies with ... (OTCQB: PBIO), Sequenom, Inc. (NASDAQ: SQNM ), ... Pharmaceutical Corp. (NASDAQ: RPTP ) and EnteroMedics ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... CHICAGO, Jan. 4, 2011 Advanced Life Sciences ... ), a biopharmaceutical company engaged in the discovery, development ... of infection, oncology and respiratory diseases, today announced that ... Healthcare Conference held January 10-12th in San Francisco. ...
... LANSING, Mich., Jan. 4, 2011 Neogen Corporation (Nasdaq: ... the second quarter of FY 2011, which ended Nov. 30, ... in the quarter rose to $6,110,000, or $0.26 per share, ... revenues increased 25% to $43,931,000, compared to the prior year,s ...
... Vaccinex, Inc. announced today that it has received clearance ... trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics ... advanced solid tumors. (Logo: http://photos.prnewswire.com/prnh/20101101/NY92716LOGO ) ... blocks the activity of semaphorin 4D (SEMA4D).  It is ...
Cached Biology Technology:Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference 2Neogen Reports 33% Increase in Net Income 2Neogen Reports 33% Increase in Net Income 3Neogen Reports 33% Increase in Net Income 4Neogen Reports 33% Increase in Net Income 5Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors 2
(Date:8/10/2015)... and TELTOW, Germany , August 10, ... (SMI), a world leader in Eye Tracking Technology for ... its OEM Eye Tracking Platform for integration into all ... contains reference designs for seamless integration of eye tracking ... reality HMDs and augmented reality smart glasses. Omnivision,s leading ...
(Date:8/6/2015)... TELTOW, Germany , August 6, 2015 ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted ... this new solution, unprecedented quality and efficiency is brought ... context-sensitive displays. For the first time, professionals and researchers ...
(Date:8/5/2015)... , August 5, 2015 ... titled "Facial Recognition Market - Global Industry Analysis, Size, ... global market for facial recognition is forecast to reach ... by increased demand for surveillance systems by civil and ... number of crimes and terrorist activities across the globe ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... University of California, Berkeley, scholar and Italian experts are at ... paintings or the art of ancient glassblowers. Instead, the team ... of fungi in Italy to create an unprecedented DNA database. ... - many of which are quite rare - are housed ...
... protein "transit system" may lie at the heart of ... , In the Sept. 17 online issue of Nature ... of a mutation that causes severe skeletal deformities in ... , The findings are surprising, said Ela Knapik, ...
... researchers at the University of Alberta in Edmonton, Canada have ... an ancient mammal that still defies classification. , The findings, ... and only comprehensive account of the creature, named Horolodectes sunae, ... Horolodectes lived about 60 million years ago, soon after the ...
Cached Biology News:Researchers barcode DNA of Venice museum's vast fungi collection 2Researchers barcode DNA of Venice museum's vast fungi collection 3Researchers barcode DNA of Venice museum's vast fungi collection 4Cellular traffic backups implicated in skeletal malformations 2Cellular traffic backups implicated in skeletal malformations 3Researchers give name to ancient mystery creature 2
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
Mouse monoclonal [15-2] to Mannose Receptor (Biotin) ( Abpromise for all tested applications). entrezGeneID: 4360 SwissProtID: P22897...
Request Info...
Mouse monoclonal [DJR3] to DcR1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: